m*********3
发帖数: 1425 | 1 AstraZeneca’s big U.S. subsidiary MedImmune, with 2200 employees, is
pruning its workforce as it adds a greater emphasis on its oncology R&D work
–but it’s not specifying just many staffers are involved.
Here’s the statement:
In April, AstraZeneca announced the sharpening of our focus on our main
therapy areas to prioritize our pipeline and improve efficiency and
productivity across the organization. This will see the company allocate
additional investment to core areas, particularly oncology. This is a
natural progression of our strategy and reflects increased pipeline
productivity, as well as the evolving shape of the overall company portfolio
with a growing proportion of specialty-care medicines.
Our pipeline has become arguably one of the best in the industry—MedImmune
’s Phase II pipeline success rate is almost double the industry average.
Biologics represent 50 percent of the overall AstraZeneca pipeline and
includes 17 Phase III biologics trials currently underway and 19 Phase II
trials.
Given this backdrop, we’re sharpening the focus on the main therapy areas,
prioritizing the pipeline, and driving greater productivity and efficiency
across the organization. As a normal course of business, we have shifted
some resources and have had minimal staffing reductions, while hiring for
critical roles in key areas such as oncology. |
f********e
发帖数: 2194 | |
p***y
发帖数: 239 | 3 oncology还在扩招啊， 裁了其他项目集中人力，财力支持oncology。最近几年
oncology是个富矿，各个公司都想去挖一把。
【在 f********e 的大作中提到】
: 裁多少人？制药裁员怎么没完没了了
|
b****i
发帖数: 138 | 4 老大帮忙内推下临床研究位置?
【在 p***y 的大作中提到】
: oncology还在扩招啊， 裁了其他项目集中人力，财力支持oncology。最近几年
: oncology是个富矿，各个公司都想去挖一把。
|
G*g
发帖数: 444 | 5 现在再进去有意义吗？bms i-o genentech merck 已经把市场吃了 PD1已经没肉了 |
w******y
发帖数: 8040 | 6 too late le bah
除非有新免疫靶点被发现
【在 p***y 的大作中提到】
: oncology还在扩招啊， 裁了其他项目集中人力，财力支持oncology。最近几年
: oncology是个富矿，各个公司都想去挖一把。
|
f****6
发帖数: 4472 | 7 PD-1只是immune modulator receptor中的一个吧，其他的比如CTLA-4，BTLA之类的也
在研究了，PD-1也不是都有效啊
楼上说的是
【在 G*g 的大作中提到】
: 现在再进去有意义吗？bms i-o genentech merck 已经把市场吃了 PD1已经没肉了
|
G*g
发帖数: 444 | 8 你看看其他这些check point那个bms genetech没在做的？而且人家都在做combo了
medimmune做得太迟了 而且treme还坐fail了 |
G*g
发帖数: 444 | 9 新一代io的方向有做不过小公司如juno az其他没多少肉了 |
j******n
发帖数: 941 | 10 图样图森破 现在公司的策略，尤其是AZ都是拿自己已有的pipeline跟PD1 PDL1做联合
治疗 谁还关系PD1单药能有多少市场。。。。 |
s*****9
发帖数: 305 | 11 For combination therapy, this year from ASCO
"Let us consider financial toxicity as any other side effect"
A challenge for all not just AZ
【在 j******n 的大作中提到】
: 图样图森破 现在公司的策略，尤其是AZ都是拿自己已有的pipeline跟PD1 PDL1做联合
: 治疗 谁还关系PD1单药能有多少市场。。。。
|
O*******f
发帖数: 926 | 12 agree
【在 j******n 的大作中提到】
: 图样图森破 现在公司的策略，尤其是AZ都是拿自己已有的pipeline跟PD1 PDL1做联合
: 治疗 谁还关系PD1单药能有多少市场。。。。
|
